CAJ | 학술논문

目的：观察依达拉奉注射液治疗急性缺血性脑卒中患者疗效及其与时间窗的关系。方法将120例急性缺血性脑卒中患者随机分成试验组和对照组，对照组仅给予常规治疗，试验组在常规治疗基础上予依达拉奉注射液治疗，2次/d，连续治疗14 d为1个疗程。分别在患者入组前、治疗后3个月采用美国国立卫生研究院卒中量表（NIHSS）进行评估，并于治疗后24 h、48 h、72 h行头颅CT观察并记录梗死面积的变化。结果试验组NIHSS疗效总有效率为83.33%，明显优于对照组的70.00%（χ2=5.70，P＜0.05）。两组治疗后3个月NIHSS评分均比治疗前明显下降（t分别=7.61、2.98，P均＜0.05）。两组治疗后3个月NIHSS评分比较，差异有统计学意义（t=5.27，P＜0.05）。试验组治疗后24 h、48 h、72 h头颅CT梗死面积与对照组同时点比较均有缩小，差异有统计学意义（t分别=4.33、3.67、4.18，P均＜0.05），且试验组治疗后72 h与治疗前的CT梗死面积差值与对照组比较，差异有统计学意义（t=3.20， P＜0.05）。将试验组按照发病时间分为发病24 h、48 h、72 h三组，三组治疗前NIHSS评分、CT梗死面积比较，差异均无统计学意义（F分别=3.05、2.98，P均＞0.05）；三组治疗后NIHSS评分、CT梗死面积比较，差异均具有统计学意义（F分别=4.92、4.01，P均＜0.05）。三组治疗后NIHSS评分、CT梗死面积两两比较，差异均有统计学意义（t分别=3.24、4.74、4.56；3.64、4.71、4.28，P均＜0.05）。结论尽早使用依达拉奉治疗急性缺血性脑卒中患者，可明显改善患者的神经功能缺损。
목적：관찰의체랍봉주사액치료급성결혈성뇌졸중환자료효급기여시간창적관계。방법장120례급성결혈성뇌졸중환자수궤분성시험조화대조조，대조조부급여상규치료，시험조재상규치료기출상여의체랍봉주사액치료，2차/d，련속치료14 d위1개료정。분별재환자입조전、치료후3개월채용미국국립위생연구원졸중량표（NIHSS）진행평고，병우치료후24 h、48 h、72 h행두로CT관찰병기록경사면적적변화。결과시험조NIHSS료효총유효솔위83.33%，명현우우대조조적70.00%（χ2=5.70，P＜0.05）。량조치료후3개월NIHSS평분균비치료전명현하강（t분별=7.61、2.98，P균＜0.05）。량조치료후3개월NIHSS평분비교，차이유통계학의의（t=5.27，P＜0.05）。시험조치료후24 h、48 h、72 h두로CT경사면적여대조조동시점비교균유축소，차이유통계학의의（t분별=4.33、3.67、4.18，P균＜0.05），차시험조치료후72 h여치료전적CT경사면적차치여대조조비교，차이유통계학의의（t=3.20， P＜0.05）。장시험조안조발병시간분위발병24 h、48 h、72 h삼조，삼조치료전NIHSS평분、CT경사면적비교，차이균무통계학의의（F분별=3.05、2.98，P균＞0.05）；삼조치료후NIHSS평분、CT경사면적비교，차이균구유통계학의의（F분별=4.92、4.01，P균＜0.05）。삼조치료후NIHSS평분、CT경사면적량량비교，차이균유통계학의의（t분별=3.24、4.74、4.56；3.64、4.71、4.28，P균＜0.05）。결론진조사용의체랍봉치료급성결혈성뇌졸중환자，가명현개선환자적신경공능결손。
Objective To observe the clinical effect of edaravone for treating patients with acute ischemic stroke and to explore its association with time windows. Methods A total of 120 patients with acute ischemic stroke were randomly di-vided into treatment group and control group. The control group was received basic treatment. The treatment group was giv-en edaravone injection that two times per day for fourteen days on the basis of basic treatment. All patients were given NIHSS scale evaluation at pre-treatment and 3 months and underwent head CT at 24 hours, 48 hours and 72 hours after treatment. The infarct sizes were compared. Results The total effective rate of treatment group was 83.33% which was significantly higher than that of the control group (χ2=5.70,P<0.05). The NIHSS scores of two groups at 3 months after treatment were significantly lower than pre-treatment (t=7.61,2.98,P<0.05). There was statistically significant difference of NIHSS score at 3 months after treatment between two groups (t=5.27,P<0.05). The head CT infarct sizes at 24 hours, 48 hours and 72 hours after treatment of treatment group were significantly smaller than control group (t=4.33,3.67,4.18, P<0.05). The difference between pre-treatment and 72 hours after treatment of treatment group was significantly greater than that of the control group(t=3.20,P<0.05). The treatment group was divided into 24 hours group, 48 hours group and 72 hours group according to the onset time. The differences of NIHSS scores and infarct sizes before treatment among 24 hours group, 48 hours group and 72 hours group were not statistically significant (F=3.05, 2.98,P>0.05) while they were significantly different after treatment(F=4.92, 4.01,P<0.05) . The differences of NHISS scores and infarct sizes were sta-tistical significance when three groups compared with each other (t=3.24, 4.74, 4.56,3.64,4.71,4.28,P<0.05). Conclu-sion Early using of edaravone in patients with acute ischemic stroke can improve the neurological function defect of patients.